The Future of Drug Repositioning: Old Drugs, New Opportunities
暂无分享,去创建一个
Michael A. Walters | Michael P. Pollastri | Gunda I. Georg | M. Walters | G. Georg | Trinh L. Doan | M. Pollastri | Gunda Ingrid Georg
[1] Michael Karin,et al. The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.
[2] Michelle R. Arkin,et al. Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.
[3] E. Tobinick. The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.
[4] Tudor I. Oprea,et al. Flow cytometry for high-throughput, high-content screening. , 2004, Current opinion in chemical biology.
[5] Donald Wlodkowic,et al. Microfluidics: Emerging prospects for anti-cancer drug screening. , 2010, World journal of clinical oncology.
[6] T. Hideshima,et al. Thalidomide in multiple myeloma. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[7] L. Zon,et al. In vivo drug discovery in the zebrafish , 2005, Nature Reviews Drug Discovery.
[8] Andrew L. Hopkins,et al. Chemical Tools for Indications Discovery , 2005 .
[9] M. Boguski,et al. Repurposing with a Difference , 2009, Science.
[10] J. Hevel,et al. Tissue injury caused by deposition of immune complexes is L-arginine dependent. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Cavalla. APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use , 2009, Nature Reviews Drug Discovery.
[12] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[13] G. Plosker. Aztreonam Lysine for Inhalation Solution , 2010, Drugs.
[14] Roland Zengerle,et al. Microfluidic platforms for lab-on-a-chip applications. , 2007, Lab on a chip.
[15] R Abagyan,et al. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs , 2007, Proceedings of the National Academy of Sciences.
[16] M. Detke,et al. Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain , 2010, Spine.
[17] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[18] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[19] C. Chong,et al. New uses for old drugs , 2007, Nature.
[20] S. Patterson,et al. Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy , 2010, Journal of Virology.
[21] M. C. Okafor. Thalidomide for Erythema Nodosum Leprosum and Other Applications , 2003, Pharmacotherapy.
[22] E. Kunkel. Systems biology in drug discovery , 2004, Nature Biotechnology.
[23] M. Detke,et al. Effects of duloxetine on painful physical symptoms associated with depression. , 2004, Psychosomatics.
[24] M. Tsang. Zebrafish: A tool for chemical screens. , 2010, Birth defects research. Part C, Embryo today : reviews.
[25] R. N. Brogden,et al. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1986, Drugs.
[26] Calum A. MacRae,et al. Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish , 2003, Circulation.
[27] Ruili Huang,et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.
[28] J. Medina-Franco,et al. The prince and the pauper. A tale of anticancer targeted agents , 2008, Molecular Cancer.
[29] J. Falgueyret,et al. Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. , 2004, The Biochemical journal.
[30] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[31] Angeleen Fleming,et al. Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects , 2010, Neuropharmacology.
[32] E. Schadt,et al. Integrative genomics and drug development. , 2009, Pharmacogenomics.
[33] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[34] A. V. van Oosterom,et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma , 2008 .
[35] R. Zengerle,et al. Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. , 2010, Chemical Society reviews.
[37] Neil Seeman,et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. , 2011, Journal of affective disorders.
[38] Maria Paola Costi,et al. Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. , 2011, Journal of medicinal chemistry.
[39] Bharat B. Aggarwal,et al. Nuclear factor-κB: its role in health and disease , 2004, Journal of Molecular Medicine.
[40] Xiaoyan Wang,et al. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. , 2009, Journal of the American Medical Informatics Association : JAMIA.
[41] A. Fliri,et al. Drug effects viewed from a signal transduction network perspective. , 2009, Journal of medicinal chemistry.
[42] Gordon A. Leonard,et al. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites , 2001, Nature Structural Biology.
[43] Lisa Jarvis. OPENING THE MEDICINE CABINET , 2010 .
[44] Camille G Wermuth,et al. Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.
[45] K. Heyne,et al. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). , 1975, Pediatrics.
[46] David W Carley,et al. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. , 2005, IDrugs : the investigational drugs journal.
[47] Tom F. Lue,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.
[48] S. Mignani,et al. Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. , 1999, Journal of medicinal chemistry.
[49] Joseph M. Tonning,et al. Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.
[50] S. Sleigh,et al. Repurposing Strategies for Therapeutics , 2010, Pharmaceutical Medicine.
[51] Neil Seeman,et al. Assessing and responding in real time to online anti-vaccine sentiment during a flu pandemic. , 2010, Healthcare quarterly.
[52] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[53] M. Backonja,et al. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. , 2010, Pain medicine.